SCHEMBL4948434

SCHEMBL4948434

CCOC(=O)Nc1ccnc(N)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.51
HSD17B10 Q99714 2/20 0.51
LMNA P02545 1/20 0.51
MAPT P10636 1/20 0.51
GRIN2D O15399 1/20 0.51
GRIN3B O60391 1/20 0.51
GRIN1 Q05586 1/20 0.51
GRIN2A Q12879 1/20 0.51
GRIN2B Q13224 1/20 0.51
GRIN2C Q14957 1/20 0.51
GRIN3A Q8TCU5 1/20 0.51
NPC1 O15118 4/20 0.49
ALDH1A1 P00352 3/20 0.49
RAB9A P51151 3/20 0.49
CYP1A2 P05177 2/20 0.49
CYP2C9 P11712 2/20 0.49
CYP2C19 P33261 2/20 0.49
HTT P42858 2/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5265137 0.79 ALDH1A1 (0.64) MAPK1HSD17B10LMNAMAPTNPC1
SCHEMBL9376173 0.79 MAP4K4 (0.49) JAK2TYK2
SCHEMBL5520232 0.77 JAK2 (0.56) HSD17B10MAPTGRIN2DGRIN3BGRIN1
SCHEMBL3836378 0.77 BCHE (0.64) MAPK1HSD17B10LMNAMAPTNPC1
SCHEMBL27838933 0.77 KDM4E (0.46) MAPK1HSD17B10MAPTNPC1ALDH1A1
SCHEMBL1250083 0.76 RAB9A (0.56) MAPK1HSD17B10LMNAMAPTNPC1
SCHEMBL7565149 0.75 MAPK1 (0.81) MAPK1HSD17B10LMNAMAPTNPC1
SCHEMBL9515087 0.75 RAB9A (0.55) MAPK1HSD17B10LMNAMAPTNPC1
Hydrochloric Acid SCHEMBL1250081 0.75 RAB9A (0.55) MAPK1HSD17B10LMNAMAPTNPC1
SCHEMBL8591930 0.75 MAPK1 (0.66) MAPK1HSD17B10LMNAMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7354946-B2 prominent growth inhibitory activity against tumor cells; cyclin dependent kinase inhibitors; colon cancer; N'-(3-t-butylisoindolino[3,2-b]oxazolidin-4-on-8-yl)-N-(4-(N-benzylpyrrolidin-3-yl)pyridin-2-yl)urea BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-04-08 US disclosed
US-20070027147-A1 Biarylurea derivatives MSD K.K. (JP) 2007-02-01 US disclosed
EP-1199306-B1 BIARYLUREA DERIVATIVES BANYU PHARMA CO LTD (JP) 2005-12-07 EP disclosed
US-6958333-B1 Biarylurea derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-10-25 US disclosed
EP-1557168-A2 Biarylurea Derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-07-27 EP disclosed
EP-1199306-A1 BIARYLUREA DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2002-04-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027147-A1 Biarylurea derivatives CDK6, CDK4, CCNI MAPK1 1152/4885HSD17B10 1895/4885LMNA 3280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.